CfO Joseph Wolk said the fitness giant has lately been in talks with the European Union, Japan and the Bill and Melinda Gates Foundation to block the supply of the candidate vaccine.
“We’re still looking at the volumes,” he said in an interview.
The Advanced Biomedical Research and Development Authority, which won a $456 million award, will work with the United States and other countries and organizations at a “universal and global price” based on their production costs, as well as on studies and expenses of progression. BARDA is the U.S. firm guilty of proposing medical countermeasures in emergency departments.
Spending will be “almost 50-50” between studies and progression and manufacturing, Wolk later said in an interview on Bloomberg Television. What J-J will eventually feature the U.S. title call. And other countries, it proposes not for profit, Wolk said. He hired an accounting firm to check the final price, he said.
J-J announced in June that he had accelerated vaccine trials with the ambition to start human studies in mid-July. Wolk said Thursday that J-J would administer to his first patients on July 22 in Belgium and the United States a week later.
Phase one trial aims to recruit more than 1,000 healthy adults over the age of 18 and 55 and 65 and 65, scientific director Paul Stoffels said in the call for results. The trials will compare the protection of the experimental vaccine, if it generates an immune reaction and the most effective regimens. J-J will conduct another phase one trial in Japan and aims to organize phase two trials in the Netherlands, Spain and Germany.
Stoffels said the company may be aware “before the end of the year or as very recent early next year.” Although it may manufacture some doses before the end of the year, they will basically be used for clinical trials, he said.
“We have the production sites, we have the filling side, we have everything we need to deliver these billion vaccines and more next year,” Stoffels said.
This story was published from a firm thread without converting the text.
Click here to read Mint ePaperLivemint.com is now on Telegram. Join the Livemint channel on your telegram and updated
Log in to our to save your favorites. It’ll only take a moment.
Your query has expired, reconnect.
You are now subscribed to our newsletters. If you can’t find any email from us, check your spam folder.